Clearmind Medicine Inc. said on Monday that the United States Patent and Trademark Office published its patent application for a combination of MDMA and N-acylethanolamines, including palmitoylethanolamide (PEA), intended for the treatment of post-traumatic stress disorder, anxiety and eating disorders.
The Vancouver-based clinical-stage biopharmaceutical company, listed on the NASDAQ under ticker CMND, said the patent application outlines how PEA may enhance MDMA’s therapeutic potency, reduce required dosing and mitigate side effects. Clearmind added that the combination therapy is designed to improve efficacy and tolerability in clinical settings.
The announcement follows the U.S. Food and Drug Administration’s finalization of guidance on psychedelic drugs in July 2026. The FDA’s document, titled Psychedelic Drugs: Considerations for Clinical Investigations, provides recommendations for sponsors developing psychedelic compounds for medical use, including trial design, subject safety and regulatory pathways for new drug applications. The agency explicitly includes MDMA within its definition of psychedelics, categorizing it alongside classic psychedelics, entactogens and empathogens.
Clearmind said the collaboration with NeuroThera Labs Inc. (TSXV: NTLX) has generated 13 patent applications globally, building on Clearmind’s broader intellectual property portfolio of 19 patent families, including 32 granted patents. The company did not specify a timeline for clinical trials or regulatory submissions related to the new patent application.
